<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897725</url>
  </required_header>
  <id_info>
    <org_study_id>000523914</org_study_id>
    <nct_id>NCT03897725</nct_id>
  </id_info>
  <brief_title>Evaluating The Acceptability and Uptake of Pre-Exposure Prophylaxis (PrEP) for Adolescent Women in The Deep South</brief_title>
  <official_title>Evaluating The Acceptability and Uptake of PrEP for Adolescent Women in The Deep South</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is designed to 1) develop a PrEP implementation plan for a general adolescent
      clinic. Investigators will develop a replicable implementation plan for providing PrEP to
      adolescents in a primary care setting; and 2) Determine the acceptability and preliminary
      effectiveness of a telehealth intervention to promote adherence in adolescents.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to PrEP</measure>
    <time_frame>1 year</time_frame>
    <description>Retention of adolescent females in PrEP care (attendance at follow-up visits) and adherence to emtricitabine/tenofovir evidenced by dried blood spot sampling</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Adolescent Behavior</condition>
  <condition>HIV/AIDS</condition>
  <condition>PrEP</condition>
  <arm_group>
    <arm_group_label>Telehealth Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will be randomized into either the control or experimental group. Participants in the intervention group will receive routine care which will follow the schedule from previous adolescent PrEP studies where participants are recommended to follow up at 4, 8, and 12 weeks and then every 3 months following initiation of PrEP. This group will also receive SMS texting every 4 weeks between in-person visits (weeks 16, 20, 28,32, 40, 44) reminding them to pick up their medication. The experimental group will also be seen in follow up every month for the first 3 months and then spaced out to visits every 3 months. The SMS texting will occur every 4 weeks between in-person visits, the experimental group will also have 2 tele-health visits (which will be conducted within a participant's home using an app) that will occur every 4 weeks between each of the traditional in-person visits to provide more frequent monitoring and counseling regarding adherence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will follow the schedule from previous adolescent PrEP studies where participants are recommended to follow up at 4, 8, and 12 weeks and then every 3 months following initiation of PrEP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telehealth Coaching</intervention_name>
    <description>Telehealth coaching to promote adherence</description>
    <arm_group_label>Telehealth Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females between 15 to 21 years old

          -  Established patients at the Adolescent Health Center

          -  HIV negative

        Exclusion Criteria:

          -  HIV positive patients

          -  patients weighing less than 35kg

          -  patients with creatinine clearance &lt;60 ml/min

          -  patients with documented osteopenia or osteoporosis or history of pathologic fractures

          -  patients with previous allergic reactions to either emtricitabine or tenofovir

          -  patients who are on post-exposure prophylaxis for HIV (they can become eligible after
             completion of therapy)

          -  patients with hepatic impairment

          -  For patients who become pregnant, they may be able to continue on PrEP after a
             discussion with their obstetrics/gynecology (OB/GYN) provider.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tina Simpson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birminghahm</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tina Simpson, MD</last_name>
    <phone>2056389345</phone>
    <email>tsimpson@peds.uab.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>William A. Daniel Adolescent Health Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tina Y Simpson, MD</last_name>
      <phone>205-638-9345</phone>
      <email>tsimpson@peds.uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Samantha Hill, MD</last_name>
      <phone>2056389345</phone>
      <email>shill@peds.uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Samantha Hill, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tina Simpson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Latesha Elopre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mercedes Morales-Aleman, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Tina Y Simpson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>See below</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>To be determined</ipd_time_frame>
    <ipd_access_criteria>To be determined</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

